RxDoctor Payments Data

Danielle Osterholzer, MD

Infectious Disease · Flint, MINPI 1659547925

Payments from drug & device makers

$589in general payments, 2019–2025

Across 35 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$218
  • Gilead$106
  • AstraZeneca$66
  • Insmed, Inc.$65
  • Viiv Healthcare Company$58
  • AbbVie$42
  • plus $32 from 1 others

What the payments were for

  • Food & beverage$589100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson12$218
Gilead7$106
AstraZeneca4$66
Insmed, Inc.4$65
Viiv Healthcare Company3$58
AbbVie(2 entities)3$42
Cepheid2$32

How this compares

$589 in reported general payments places this provider in the 60th percentile of 257 infectious disease providers in Michigan.

See all infectious disease providers in Michigan

Medicare billing

Part B allowed, 2024
$35,161
Medicare patients
121
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala193$833,874
CabenuvaCabotegravir/Rilpivirine18$113,821
DescovyEmtricitabine/Tenofov Alafenam24$55,022
DovatoDolutegravir Sodium/Lamivudine18$50,720
TriumeqAbacavir/Dolutegravir/Lamivudi12$42,784
Breo ElliptaFluticasone/Vilanterol12$4,827
Cefepime Hcl14$1,808
Linezolid22$1,398
Meropenem14$1,301
Ventolin HfaAlbuterol Sulfate20$1,125
Atorvastatin Calcium61$475
Acyclovir25$278
Metronidazole21$243
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$190
Doxycycline Hyclate14$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$106$888,896217 claims
Viiv Healthcare CompanyCabenuva, Dovato, Triumeq$58$207,32648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 257 infectious disease providers in Michigan.

Other infectious disease in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →